Compare Moderna, Inc. (MRNA) vs ON Holding AG (ONON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs ON Holding AG — how do they compare? Moderna, Inc. trades at $218.64 (market cap $78.65B), while ON Holding AG trades at $35 (market cap $11.38B). The key difference: Moderna, Inc. is far larger — about 6.9× ON Holding AG's market cap, and Moderna, Inc. is trading nearer its 52-week high, ON Holding AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and ON Holding AG for 22 Days on average.
| MRNA | ONON | |
|---|---|---|
Market Cap | $78.65B | $11.38B |
Volume | 37,373,437 | 13,732,872 |
Sector | Health | Consumer Cyclical |
52-Week High | $203.46 | $50.63 |
52-Week Low | $22.36 | $26.76 |
Typical Hold Time | 59 Days | 22 Days |
Enterprise Value | $74.80B | $10.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
ONON trades at $34.79, up 4.73% today, reflecting strong momentum. The stock shows bullish technical signals with support at $33 and resistance at $35. Fundamentally, the company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $0.44 exceeding expectations. Revenue reached $3.01 billion in 2025, with a net income margin of 12.3%. Recent news highlights a $1 billion share buyback plan and ambitious 2029 targets.
The outlook is positive, driven by earnings growth, strategic expansion, and strong analyst support. Key risks include competitive pressures and market volatility. Analysts maintain a consensus buy rating with a $42.26 price target, suggesting potential upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
